XL647-A multitargeted tyrosine kinase inhibitor: Results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib

M. Catherine Pietanza, Thomas James Lynch, Primo N Lara, John Cho, Ronald H. Yanagihara, Nandagopal Vrindavanam, Naveed Mahfooz Chowhan, Shirish M. Gadgeel, Nathan A. Pennell, Roel Funke, Ben Mitchell, Heather A. Wakelee, Vincent A. Miller

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Fingerprint

Dive into the research topics of 'XL647-A multitargeted tyrosine kinase inhibitor: Results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib'. Together they form a unique fingerprint.

Medicine & Life Sciences